Durability of CAR T-cell therapy response may depend on pretreatment disease cargo in leukemia patients Albeit most patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) experienced accomplish response after treatment with a type of CAR T-cell immunotherapy, pretreatment disease cargo impacted the durability of the responses and long-term survival, according to data from a clinical trial introduced here at the…